Medications for Human Immunodeficiency Virus I Infection

15 results

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents aged 12 and older (weighing at least 35 kg) who are virologically suppressed and stable on their current antiretroviral therapy, with no treatment failure history or known resistance to its components.

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • evotaz

    (atazanavir and cobicistat)
    E.R. Squibb & Sons, L.L.C.
    EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

  • fuzeon

    (Enfuvirtide)
    Genentech, Inc.
    FUZEON® is indicated for the treatment of HIV-1 infection in treatment-experienced patients who show evidence of ongoing HIV-1 replication despite receiving antiretroviral therapy, in combination with other antiretroviral agents.

  • pifeltro

    (doravirine)
    Merck Sharp & Dohme LLC
    PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    Janssen Products LP
    PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

  • prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    A-S Medication Solutions
    PREZCOBIX is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥40 kg), either treatment-naïve or experienced, when used with other antiretroviral agents and in the absence of specific darunavir resistance-associated substitutions.

  • prezista

    (darunavir)
    Janssen Products LP
    PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 years and older.

  • prezista

    (darunavir)
    Physicians Total Care, Inc.
    PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in both adult and pediatric patients aged 3 years and older. This is supported by clinical trial data assessing HIV-1 RNA levels and CD4+ cell counts.